Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis (Q36042131)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

8 references

12 March 2019

13 March 2019

22 April 2019

22 June 2019

17 June 2019

2 October 2019

17 November 2019

30 January 2021

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis (English)

1 reference

Europe PubMed Central

11 August 2017

atopic dermatitis

7 references

12 March 2019

13 March 2019

22 April 2019

22 June 2019

17 June 2019

2 October 2019

17 November 2019

mechanism of action

1 reference

2 October 2019

1 reference

17 November 2019

calcineurin inhibitor

1 reference

30 January 2021

systematic review

1 reference

based on heuristic

inferred from title

author name string

Elaine C Siegfried

1

1 reference

Europe PubMed Central

11 August 2017

Jennifer C Jaworski

2

1 reference

Europe PubMed Central

11 August 2017

Jennifer D Kaiser

3

1 reference

Europe PubMed Central

11 August 2017

Adelaide A Hebert

4

1 reference

Europe PubMed Central

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 June 2016

9 references

Europe PubMed Central

11 August 2017

12 March 2019

13 March 2019

22 April 2019

22 June 2019

17 June 2019

2 October 2019

17 November 2019

30 January 2021

9 references

Europe PubMed Central

11 August 2017

12 March 2019

13 March 2019

22 April 2019

22 June 2019

17 June 2019

2 October 2019

17 November 2019

30 January 2021

16

1 reference

Europe PubMed Central

11 August 2017

75

1 reference

Europe PubMed Central

11 August 2017

copyright license

Creative Commons Attribution 4.0 International

8 references

Europe PubMed Central

12 March 2019

Europe PubMed Central

13 March 2019

Europe PubMed Central

22 April 2019

Europe PubMed Central

22 June 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

17 November 2019

Europe PubMed Central

30 January 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/s12887-016-0607-9

0 references

Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Association Between Malignancy and Topical Use of Pimecrolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Optimizing outcomes for paediatric atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

"Unknown Risks" of non-steroid topical medications for atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Calcineurin inhibitors and rapamycin: cancer protection or promotion?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Adverse effects of topical glucocorticosteroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Global estimate of the incidence of clinical pneumonia among children under five years of age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Managing childhood atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

The use of corticosteroids and corticosteroid phobia in atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Atopic dermatitis in childhood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Adult height in patients with childhood onset atopic dermatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Cushing Syndrome From Percutaneous Absorption of Triamcinolone Cream

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

2 October 2017

Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

11 July 2018

Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Topical immune modulation and risk of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Safety information for tacrolimus: present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Atopic dermatitis and tacrolimus in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Safety and efficacy of tacrolimus ointment 0.1% (Protopic) in atopic dermatitis: a Canadian open-label multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Acute and maintenance treatment of atopic dermatitis in children – two comparative studies with fluticasone propionate (0.05%) cream

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895880

23 September 2018

Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients

1 reference

https://api.crossref.org/works/10.1186%2FS12887-016-0607-9

21 January 2018

Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year

1 reference

https://api.crossref.org/works/10.1186%2FS12887-016-0607-9

21 January 2018

Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcineurin inhibitors for the treatment of atopic dermatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential hazards of topical steroid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are lifetime prevalence of impetigo, molluscum and herpes infection really increased in children having atopic dermatitis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute respiratory illness in an American community. The Tecumseh study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27267134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12887-016-0607-9

1 reference

Europe PubMed Central

11 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36042131&oldid=1980521339"